Shortness of breath with daily activities questionnaire: Validation and responder thresholds in patients with chronic obstructive pulmonary disease

BMJ Open

Volumn 3, Issue 10, 2013, Pages

  Watkins, Michael L ^a   Wilcox, Teresa K ^b   Tabberer, Maggie ^c   Brooks, Jean M ^c   Donohue, James F ^d   Anzueto, Antonio ^e   Chen, Wen Hung ^b   Crim, Courtney ^a  

^a GLAXOSMITHKLINE   (United States)

^b EVIDERA   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY QUESTIONNAIRE; CLINICAL ASSESSMENT; CLINICIAN GLOBAL IMPRESSION OF CHANGE QUESTION; CLINICIAN GLOBAL IMPRESSION OF DYSPNEA SEVERITY; CONTROLLED STUDY; CONVERGENT VALIDITY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INHALER; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT GLOBAL ASSESSMENT OF CHANGE QUESTION; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; SHORTNESS OF BREATH WITH DAILY ACTIVITIES QUESTIONNAIRE; SMOKING; SPIROMETRY; TEST RETEST RELIABILITY; TREATMENT RESPONSE; UNITED STATES;

EID: 84887960355     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003048     Document Type: Article

References (16)

1. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
2. Wilcox TK, Chen W-H, Howard KA, et al. Reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in COPD. American Thoracic Society - 106th International Conference. 2010;181:A5429.
3. Howard K, Berry P, Petrillo J, et al. Development of the Shortness of Breath with Daily Activities questionnaire (SOBDA). Value Health 2012;15:1042-50.
4. Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf (accessed 4 Apr 2013).
5. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
6. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-87.
7. Nunnally JC, Bernstein IH. Psychometric theory. 3rd edn. New York: McGraw-Hill, Inc., 1994.
8. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70.
9. Wyrwich K, Tierney W, Wolinsky F. Further evidence supporting a SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-73.
10. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnoea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002;121:688-96.
11. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348:2618-25.
12. Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005;26:420-8.
13. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85(Suppl. B):2531.
14. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
15. Hays R, Anderson R, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of life assessment in clinical trials. New York, NY: Oxford University Press, 1998: 167-82.
16. Schunemann HJ, Puhan M, Goldstein R, et al. Measurement properties and interpretability of the chronic respiratory disease questionnaire (CRQ). COPD 2005;2:81-9.